Amarin Appoints Tom Reilly as New Chief Financial Officer
June 06 2022 - 8:15AM
Amarin Corporation plc (NASDAQ:AMRN) today announced the
appointment of Tom Reilly as Chief Financial Officer, effective
June 20, 2022. The appointment follows the resignation of Michael
W. Kalb who will leave the Company to pursue other interests after
a brief transition period.
“We are delighted to welcome Tom Reilly to the Amarin executive
leadership team. Tom’s significant financial leadership experience
across large global pharma and biotechnology companies as well as
his proven track record leading financial planning and analysis
within international and commercial operations will be a great
asset to Amarin as we expand around the world. I look forward to
working closely with Tom to execute on our European and
international objectives,” said Karim Mikhail, president and chief
executive officer of Amarin. “I would like to thank Mike for his
years of service to Amarin. On behalf of the entire Amarin team, I
wish him continued success in his future endeavors.”
“Tom’s appointment exemplifies our commitment to enhance our
leadership team and board with the right talent to support the
Company’s BOLD vision to stop cardiovascular disease from being a
leading cause of death worldwide,” concluded Mr. Mikhail.
“I am excited to be joining Amarin at this important juncture in
the Company’s global expansion, and I look forward to bringing my
experiences to bear in executing disciplined financial management
and leadership that will support the Company’s growth in the years
to come,” said Mr. Reilly.
Tom Reilly is an experienced senior leader with significant
expertise in corporate and commercial finance in the pharmaceutical
and biotechnology sectors. Most recently, he served as Chief
Financial Officer for Cara Therapeutics, where he was responsible
for leading all aspects of Cara’s financial operations and
planning. Prior to his role at Cara, Mr. Reilly served as Head of
Finance for the U.S. General Medicines unit at Allergan, where he
led all financial management for that business. Prior to Allergan,
Mr. Reilly spent 14 years with Novartis where he served in roles of
increasing responsibility, including Finance Head for the Novartis
Oncology Development unit, CFO for Novartis Pharma Austria,
Financial Controller for Novartis USA’s Pharmaceutical Division as
well as a series of roles supporting Novartis’ financial planning
and analysis and accounting. Earlier in his career, Mr. Reilly
served in financial planning and finance roles at Pharmacia.
Mr. Reilly holds a Bachelor of Science in Finance from Manhattan
College and a Master of Business Administration in Accounting from
Seton Hall University.
About Amarin
Amarin is an innovative pharmaceutical company leading a new
paradigm in cardiovascular disease management. From our scientific
research foundation to our focus on clinical trials, and now our
global commercial expansion, we are evolving and growing rapidly.
Amarin has offices in Bridgewater, New Jersey in the United States,
Dublin, in Ireland, Zug in Switzerland, and other countries in
Europe as well as commercial partners and suppliers around the
world. We are committed to rethinking cardiovascular risk through
the advancement of scientific understanding of the impact on
society of significant residual risk that exists beyond traditional
therapies, such as statins for cholesterol management.
Availability of Other Information About
Amarin Amarin communicates with its investors
and the public using the company website (www.amarincorp.com) and
the investor relations website (investor.amarincorp.com), including
but not limited to investor presentations and FAQs, Securities and
Exchange Commission (“SEC”) filings, press releases, public
conference calls and webcasts. The information that Amarin posts on
these channels and websites could be deemed to be material
information. As a result, Amarin encourages investors, the media
and others interested in Amarin to review the information that is
posted on these channels, including the investor relations website,
on a regular basis. This list of channels may be updated from time
to time on Amarin’s investor relations website and may include
social media channels. The contents of Amarin’s website or these
channels, or any other website that may be accessed from its
website or these channels, shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of U.S. securities laws. These forward-looking
statements are not promises or guarantees and involve substantial
risks and uncertainties. A list and description of these risks,
uncertainties and other risks associated with an investment in
Amarin can be found in Amarin's filings with the SEC, including
Amarin’s annual report on Form 10-K for the year ended December 31,
2021, and quarterly report on Form 10-Q for the quarter ended March
31, 2022. Existing and prospective investors are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date they are made. Amarin undertakes no
obligation to update or revise the information contained in its
forward-looking statements, whether as a result of new information,
future events or circumstances or otherwise. Amarin’s
forward-looking statements do not reflect the potential impact of
significant transactions the company may enter into, such as
mergers, acquisitions, dispositions, joint ventures or any material
agreements that Amarin may enter into, amend or
terminate.
Amarin Contact Information
Investor Inquiries:Lisa DeFrancescoInvestor Relations Amarin
Corporation plcinvestor.relations@amarincorp.com (investor
inquiries)
Media Inquiries:Mark MarmurCorporate Communications, Amarin
Corporation plcPR@amarincorp.com (media inquiries)
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024